Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting INHBE
- Development stage
- Preclinical
- Lead developer
- China Medical System
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
CMS-D008 is an investigational small interfering RNA (siRNA) therapeutic developed by Hainan Kangzhe Weisheng Technology for the treatment of overweight and obesity. The drug utilizes RNA interference (RNAi) to specifically silence the expression of the **INHBE** (Inhibin subunit beta E) gene. INHBE is a member of the transforming growth factor-beta (TGF-β) superfamily and is primarily expressed in the liver. Genetic studies have linked INHBE variants to metabolic regulation, suggesting that its downregulation is associated with improved fat distribution and protection against metabolic disorders such as type 2 diabetes. By reducing INHBE levels, CMS-D008 aims to modulate energy metabolism and promote weight loss. The program is currently in the preclinical stage of development.
- Other names
- siRNA targeting INHBE
02
Targets
INHBE (Inhibin beta E chain)
Beyond the preview
Go deeper on siRNA targeting INHBE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting INHBE.